The role of matrix metalloproteinases in patients with pulmonary hypertension: data from a prospective study.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
20 12 2021
Historique:
received: 13 06 2021
accepted: 08 12 2021
entrez: 21 12 2021
pubmed: 22 12 2021
medline: 1 2 2022
Statut: epublish

Résumé

Despite several therapies, pulmonary hypertension (PH) is still a severe disease which can lead to right heart failure. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are involved in cardiac and vascular remodeling in PH. Therefore, these biomarkers play an important role in PH patients. This study investigated whether TIMP-4, MMP-2, and N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) plasma levels are useful in assessing the severity of PH and other clinical or echocardiographic parameters. The concentrations of MMP-2, TIMP-4, and NT-proBNP in 68 PH patients were compared with those of 12 controls without PH. All patients underwent a physical examination, echocardiography, and were checked for the presence of cardiovascular risk factors; also, plasma concentrations of MMP-2, TIMP-4, NT-proBNP, total cholesterol, and triglycerides were determined. In PH patients, significantly elevated plasma levels of TIMP-4 (PH: 2877.99 ± 1363.78 pg/ml, control: 2028.38 ± 762.67 pg/ml, p = 0.0068) and NT-proBNP ( PH: 2405.00 pg/ml-5423.47 ± 6703.38 pg/ml, control: 411.0000 pg/ml-421.75 ± 315.37 pg/ml, p = 0.01) were detected. We also observed that MMP-2 and NT-proBNP were significantly increased in patients with higher WHO functional class (p = 0.001 for MMP-2, p = 0.008 for NT-proBNP), higher pressure in the pulmonary artery (p = 0.002 for MMP-2, p = 0.001 for NT-proBNP), and more severe tricuspid regurgitation (p = 0.001 for MMP-2, p = 0.009 for NT-proBNP). TIMP-4 was elevated in patients with more severe pressure in the pulmonary artery (p = 0.006). The plasma levels of TIMP-4 and NT-proBNP are higher in PH patients. MMP-2 and NT-proBNP correlates with different PH parameters severity (WHO functional class, sPAP severity, TV regurgitation severity). Therefore, plasmatic levels of MMP-2 and NT-proBNP at this kind of patients reflect disease severity and may have a prognostic role. MMP-2 can help assess the beneficial effects of PH pharmacotherapy on tissue remodeling. These remodeling biomarkers may not have a diagnostic value but they have the potential to predict survival. Nevertheless, a greater understanding of the involvement of MMPs in PH is mandatory to further explore the prognostic role and the possibilities of therapeutic MMP inhibition in PH.

Sections du résumé

BACKGROUND
Despite several therapies, pulmonary hypertension (PH) is still a severe disease which can lead to right heart failure. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are involved in cardiac and vascular remodeling in PH. Therefore, these biomarkers play an important role in PH patients. This study investigated whether TIMP-4, MMP-2, and N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) plasma levels are useful in assessing the severity of PH and other clinical or echocardiographic parameters.
METHODS
The concentrations of MMP-2, TIMP-4, and NT-proBNP in 68 PH patients were compared with those of 12 controls without PH. All patients underwent a physical examination, echocardiography, and were checked for the presence of cardiovascular risk factors; also, plasma concentrations of MMP-2, TIMP-4, NT-proBNP, total cholesterol, and triglycerides were determined.
RESULTS
In PH patients, significantly elevated plasma levels of TIMP-4 (PH: 2877.99 ± 1363.78 pg/ml, control: 2028.38 ± 762.67 pg/ml, p = 0.0068) and NT-proBNP ( PH: 2405.00 pg/ml-5423.47 ± 6703.38 pg/ml, control: 411.0000 pg/ml-421.75 ± 315.37 pg/ml, p = 0.01) were detected. We also observed that MMP-2 and NT-proBNP were significantly increased in patients with higher WHO functional class (p = 0.001 for MMP-2, p = 0.008 for NT-proBNP), higher pressure in the pulmonary artery (p = 0.002 for MMP-2, p = 0.001 for NT-proBNP), and more severe tricuspid regurgitation (p = 0.001 for MMP-2, p = 0.009 for NT-proBNP). TIMP-4 was elevated in patients with more severe pressure in the pulmonary artery (p = 0.006).
CONCLUSIONS
The plasma levels of TIMP-4 and NT-proBNP are higher in PH patients. MMP-2 and NT-proBNP correlates with different PH parameters severity (WHO functional class, sPAP severity, TV regurgitation severity). Therefore, plasmatic levels of MMP-2 and NT-proBNP at this kind of patients reflect disease severity and may have a prognostic role. MMP-2 can help assess the beneficial effects of PH pharmacotherapy on tissue remodeling. These remodeling biomarkers may not have a diagnostic value but they have the potential to predict survival. Nevertheless, a greater understanding of the involvement of MMPs in PH is mandatory to further explore the prognostic role and the possibilities of therapeutic MMP inhibition in PH.

Identifiants

pubmed: 34930125
doi: 10.1186/s12872-021-02424-5
pii: 10.1186/s12872-021-02424-5
pmc: PMC8686623
doi:

Substances chimiques

Biomarkers 0
Peptide Fragments 0
Tissue Inhibitor of Metalloproteinases 0
pro-brain natriuretic peptide (1-76) 0
Natriuretic Peptide, Brain 114471-18-0
MMP2 protein, human EC 3.4.24.24
Matrix Metalloproteinase 2 EC 3.4.24.24

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

607

Informations de copyright

© 2021. The Author(s).

Références

Am J Respir Crit Care Med. 2006 Apr 1;173(7):744-50
pubmed: 16415273
J Am Coll Cardiol. 1998 Jan;31(1):202-8
pubmed: 9426041
Korean Circ J. 2011 Feb;41(2):83-90
pubmed: 21430993
Acad Emerg Med. 2003 Mar;10(3):198-204
pubmed: 12615582
Am J Hypertens. 2004 Sep;17(9):764-9
pubmed: 15363817
Echocardiography. 2005 Jul;22(6):473-8
pubmed: 15966931
Am Heart J. 2004 Jan;147(1):60-5
pubmed: 14691420
J Biol Chem. 1996 Nov 29;271(48):30375-80
pubmed: 8939999
Pathol Res Pract. 2002;198(6):403-12
pubmed: 12166897
J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S55-S66
pubmed: 19555859
Cardiovasc Res. 2001 Aug 15;51(3):601-7
pubmed: 11476751
Circulation. 2018 May 15;137(20):e578-e622
pubmed: 29650544
Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):346-52
pubmed: 8756805
Nucl Med Commun. 2012 May;33(5):459-63
pubmed: 22262242
Circulation. 2005 May 10;111(18):2391-7
pubmed: 15883225
Am J Physiol Heart Circ Physiol. 2021 Jul 1;321(1):H242-H252
pubmed: 34085841
Cardiovasc Res. 2006 Feb 15;69(3):562-73
pubmed: 16405877
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-41
pubmed: 24355639
Eur Respir J. 2012 Sep;40(3):766-82
pubmed: 22523364
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Am J Physiol. 1998 May;274(5):H1684-9
pubmed: 9612380
Clin Exp Pharmacol Physiol. 2007 Jul;34(7):594-600
pubmed: 17581214
Swiss Med Wkly. 2021 Jun 07;151:w20486
pubmed: 34097745
Am J Cardiol. 2004 Sep 1;94(5):676-8
pubmed: 15342310
Eur Respir J. 2005 May;25(5):834-42
pubmed: 15863640
Am J Pathol. 1997 Apr;150(4):1349-60
pubmed: 9094991
Chest. 2004 Oct;126(4):1330-6
pubmed: 15486400
Am J Cardiol. 2006 May 1;97(9):1386-90
pubmed: 16635617
Biomarkers. 2010 Sep;15(6):523-32
pubmed: 20528622
Circ Res. 2003 May 2;92(8):827-39
pubmed: 12730128
Eur Heart J Cardiovasc Imaging. 2017 Nov 1;18(11):1191-1204
pubmed: 28329307
Int J Cardiol. 2016 Nov 15;223:821-826
pubmed: 27575785
Am J Physiol Lung Cell Mol Physiol. 2009 Dec;297(6):L1013-32
pubmed: 19748998
Anatol J Cardiol. 2017 Jan;17(1):8-17
pubmed: 27182612
Toxicol Pathol. 1991;19(4 Pt 1):447-57
pubmed: 1813988
J Vasc Surg. 1996 Jul;24(1):82-92
pubmed: 8691532
Biomarkers. 2008 May;13(3):270-81
pubmed: 18415800
Heart Fail Rev. 2007 Mar;12(1):23-36
pubmed: 17345160

Auteurs

Adriana Marc (A)

Iuliu Haţieganu" University of Medicine and Pharmacy, 400012, Cluj-Napoca, Romania.
Department of Cardiology, Emergency County Hospital Baia Mare, 430031, Baia Mare, Romania.

Calin Pop (C)

Department of Cardiology, Emergency County Hospital Baia Mare, 430031, Baia Mare, Romania. medicbm@yahoo.com.
Faculty of Medicine Arad, West Vasile Goldis University, 310025, Arad, Romania. medicbm@yahoo.com.

Adela-Viviana Sitar-Taut (AV)

Internal Medicine Department, 4Th Medical Clinic "Iuliu Haţieganu" University of Medicine and Pharmacy, 400012, Cluj-Napoca, Romania.

Liviuta Budisan (L)

Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu - Hatieganu University of Medicine and Pharmacy, 400337, Cluj-Napoca, Romania.

Ioana Berindan-Neagoe (I)

Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu - Hatieganu University of Medicine and Pharmacy, 400337, Cluj-Napoca, Romania.

Dana Pop (D)

Iuliu Haţieganu" University of Medicine and Pharmacy, 400012, Cluj-Napoca, Romania.
Clinical Rehabilitaton Hospital, Cardiology, 400437, Cluj-Napoca, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH